Status:

RECRUITING

Gracie Diet for Gastroesophageal Reflux Disease

Lead Sponsor:

Johns Hopkins University

Conditions:

Gastroesophageal Reflux

GERD

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The goal of this clinical trial is to learn if dietary changes can help improve gastroesophageal reflux disease (GERD) symptoms. The main question\[s\] it aims to answer whether the Gracie Diet is an ...

Detailed Description

GERD, is a common and chronic world-wide disease. Cardinal symptoms of this condition are heartburn-regurgitation, and sometimes with extra-intestinal symptoms that can affect patients' quality of lif...

Eligibility Criteria

Inclusion

  • Age 18 years or older at registration.
  • Patients with ongoing symptoms of GERD: heartburn (pyrosis) mid-sternal chest pain, regurgitation of fluid or food, development of esophageal inflammation that may lead to swallowing dysfunction, or extraesophageal manifestations (i.e. cough, bronchospasms, and hoarseness).
  • Use of one of the following PPI medications: omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole or dexlansoprazole. And/or use of one of the following H2 blockers medications as well: famotidine, cimetidine, ranitidine or nizatidine.
  • Willing to comply with the Gracie diet regimen

Exclusion

  • Age \< than 18 years.
  • Patients unable to speak English.
  • Pregnancy or nursing.
  • Complicated oropharyngeal dysphagia or other condition with risk for aspiration from oral ingestion.
  • Exclusion of other causes of symptoms as mechanical gastrointestinal obstruction, Barrett's esophagus and cancer of the esophagus by standard radiographic or endoscopic test evidenced in the medical record chart.
  • A prior surgery of the upper gastrointestinal tract.
  • Failure to give informed consent.
  • Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study.

Key Trial Info

Start Date :

November 13 2020

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2025

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT04360252

Start Date

November 13 2020

End Date

December 1 2025

Last Update

January 17 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States, 21224